Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis

Fig. 2

Candidate driving genetic alterations and their druggability in AYA cancers. An analysis of WES/WTS and OncoScan™ with our heuristic annotation identified level-1 candidate genetic alterations. By analyzing DAVID and DGIdb, the representative pathway of AYA cancers and druggability were also identified. The druggability is indicated by illustrations of pills; red indicates a direct inhibitor of a candidate target gene, and blue/yellow indicates an inhibitor of a pathway that includes the candidate alterations. AYA07 was excluded from the candidate gene search due to the hypermutation. All candidate genetic alterations are described in Additional file 4: Table S3

Back to article page